Due to market rumors that Peking University Pharmaceuticals (000788.SZ) will cooperate with Shionogi of Japan to develop oral drugs for the new crown, from the 9th to the 16th of this month, Peking University Pharmaceuticals harvested six consecutive boards, and the stock price rose from the closing price on March 8. 7.45 yuan / share It jumped to the closing price of 13.2 yuan per share on March 16, an increase of 77.2%.
Peking University Pharmaceuticals, which “can’t sit still”, has issued clarification announcements many times, saying that the company has never carried out research and development of new crown special drugs, nor has it discussed cooperation with Japan’s Shionoyi about new crown special drugs. However, on the 17th, Peking University Medicine continued to trade within the daily limit, closing up 4.92%.
It is worth mentioning that on the investor interaction platform, Yuan Yufei, secretary of the board of directors of Peking University Pharmaceuticals, also wrote a poem to reply to investors, “My family has a young girl who has grown up and has never married a Dongying man. The company is busy for you to refute rumors, think more about rational investment, there is no grass in the world, don’t be unrequited in love with a flower, and you are welcome to join us again after rationality returns.” Directly point to the company’s recent stock price fluctuations related to hot money speculation.
The Secretary of the Board of Directors of Peking University Pharmaceuticals wrote a poem to reply to investors. Image source: Shenzhen Stock Exchange Interactive Platform
After 8 days of 6 consecutive board companies, the stock price still rises by the limit
As the popularity of the concept of oral medicine for the new crown has risen, the stock prices of many concept stocks have been taken away, but there are also many companies with “concept”. One of them is Peking University Medicine, which is rumored to have signed a contract with the Japanese pharmaceutical company Shionogi for the new crown special medicine.
The reporter noticed that as early as August last year, there were investors on Xueqiu and other platforms that speculated that “Peking University Pharmaceuticals will cooperate with Shionogi”. The source of this speculation is that Ping An of China and Shionogi of Japan established a joint venture company, Ping An Shionogi Co., Ltd. At the same time, Peking University Pharmaceuticals “officially announced” that Ping An of China will become the company’s new controlling shareholder.
Some investors further believe that, as a pharmaceutical listing platform under Ping An, Peking University Hospital will be expected to undertake Shionoyi’s domestic pharmaceutical business. With the news in March of this year that Shionogi announced that his new crown oral drug is expected to be approved by the Japanese government in the near future, Peking University Hospital has become the target of being hunted by secondary market funds.
From the 9th to the 16th of this month, Peking University Pharmaceuticals gained six consecutive boards, and the stock price jumped from the closing price of 7.45 yuan per share on March 8 to the closing price of 13.2 yuan per share on March 16. On the 17th, Peking University Pharmaceuticals closed the daily limit for a time. As of the close, it rose 4.92% to close at 13.85 yuan per share.
After the stock price rose for days, Peking University Pharmaceuticals “couldn’t sit still”. The company issued a series of clarification announcements on the 11th and 16th, saying that the company has never carried out the research and development of new crown special drugs, nor has it discussed cooperation with Japan’s Shionoyi about new crown special drugs.
The company also clarified its equity relationship with China Ping An. Peking University Pharmaceuticals stated that as of the date of the announcement, the equity transfer and asset delivery of the company’s original actual controllers, Peking University Founder Group Co., Ltd. and Peking University Medical Industry Group Co., Ltd., have not yet been completed. However, due to the reorganization of Founder Group and the audit report with a qualified opinion on the company’s annual report, there are still uncertainties in the aforementioned risk matters. This means that Peking University Medicine has not changed its surname to “Ping An”.
The company has repeatedly clarified that the enthusiasm for funds in the secondary market has cooled down, but the residual warmth is still there.
The secretary of the board of directors wrote a poem and replied: “However, the epidemic has become a hot spot, and hot money has made waves again”
It is worth noting that Yuan Yufei, Secretary of the Board of Directors of Peking University Pharmaceuticals, also wrote poems on the investor interaction platform to clarify the company’s new crown oral drug hotspots.
Yuan Yufei wrote in his poems, “My family has a daughter who has just grown up and has never married a Dongying man. However, the epidemic has become hot, and hot money has made waves. The company is busy for you to refute rumors, think more about rational investment, and there is no grass anywhere in the world. Don’t be unrequited in love with a flower, and welcome to join us again after rationality returns.”
In response to the “hot money making waves and making waves” mentioned by Yuan Yufei, the secretary of the board of directors, on the investor platform, Yuan Yufei himself told the “Daily Economic News” reporter that this remark is that the company believes that the rise in the market is mainly caused by hot money speculation.
The reporter noticed that there are indeed many well-known brokerage seats involved in this round of rising prices of Peking University Pharmaceuticals.
Among them, Huaxin Securities Ningbo Branch bought 32.6281 million yuan on March 16, bought 32.6988 million yuan again on March 17, and sold 35.8393 million yuan. Haitong Securities Lishui Jiefang Street Sales Department bought 18.5948 million yuan from March 14 to 15, and sold 18.4071 million yuan on March 16. Orient Fortune Securities Lhasa Tuanjie Road No. 1 business department bought 29.6228 million yuan on March 16, and sold 30.3882 million yuan on the 17th.
It can be seen that the hot money entered the market in a big way in the early stage of Peking University Pharmaceutical’s stock price rise, and then quickly exited the market in the past two days after the company issued clarification announcements one after another.
Yuan Yufei, the secretary of the board of directors who wrote the poem to reply to investors, had previously served as a pharmaceutical industry analyst at the Research Institute of Everbright Securities Co., Ltd., and deputy general manager of the pharmaceutical business department of Peking University Founder Group Co., Ltd. In May 2021, he was appointed as the Secretary of the Board of Directors of Peking University Pharmaceuticals. Yuan Yufei told reporters that the reply on the investor interaction platform also hopes to remind investors to invest rationally and pay attention to risks.
Cover image source: Visual China
